Know Cancer

forgot password

A Prospective Histopathologic Study of Dynamic Contrast Enhanced MRI for Prostate Cancer Delineation and Characterization With the APT-MRI System

18 Years
Not Enrolling
Prostate Cancer

Thank you

Trial Information

A Prospective Histopathologic Study of Dynamic Contrast Enhanced MRI for Prostate Cancer Delineation and Characterization With the APT-MRI System

Accurate spatial delineation and biologic characterization of tumors within the prostate
gland by non-invasive means, such as MR imaging, stands to impact the spectrum of prostate
cancer care. At present there are no imaging techniques that can accurately delineate tumor
extent. With dynamic contrast enhanced MRI (DCE-MRI), signal intensity can be plotted over
time for various regions of interest within the prostate, and reflect physiological
parameters such as tissue perfusion, blood flow, vascular density and vascular permeability.
Preliminary studies suggest that malignant tumors demonstrate a more rapid and intense
uptake of contrast, as well as a more rapid washout compared with the normal peripheral
zone. However, histopathologic confirmation of these findings has been limited.

This study strives to establish a correlation between K(trans) calculated from DCE-MRI data
and the corresponding tissue histopathology. This will be achieved by acquiring needle
biopsies with the APT-MRI (Access to Prostate Tissue under MRI-guidance) system in accurate
spatial and temporal reference to DCE-MR images. The study will accrue 80 patients over a
2-year period with the primary analysis relating K(trans) to the probability of malignancy
using Generalized Estimating Equations.

Patients who have undergone a TRUS-guided biopsy for suspected prostate cancer or patients
with a pathological diagnosis of prostate cancer will be potential candidates for
enrollment. Prior to the procedure, blood will be drawn and urine collected to measure PSA
level and for protein profiling. Patients will then undergo endorectal coil MR imaging of
the prostate gland, including conventional anatomic imaging and dynamic-contrast-enhanced
MRI. During MR imaging, 4 to 10 needle biopsy cores of the prostate will be obtained using
a trans-rectal needle guide system (APT-MRI). The ability to obtain prostate biopsy cores
from all prostatic subzones and sites of interest will be documented, as will the overall
procedure time and acute toxicities associated with the procedure. Histopathology and
laboratory results of needle core biopsies will be compared to corresponding DCE-MRI
measurements, prior TRUS-biopsy results, and/or prostatectomy specimens. This procedure may
be repeated at a later time through the patient's course of observation, therapy, or follow

This is not a therapeutic trial. Patients admitted to this protocol will only be admitted
to other protocols of experimental treatments if they also specifically meet the eligibility
criteria for those protocols. Patients may derive benefit from the MRI-guided biopsy, which
will be stated in the protocol consent document.

Inclusion Criteria


- ECOG performance status 0 or 1.

- Patients with a TRUS-guided biopsy for suspected prostate cancer in the past twelve
months, or patients with pathologically confirmed adenocarcinoma of the prostate
gland and who have not received definitive local therapy.

- Age greater than or equal to 18 years.

- Informed consent: All patients must sign a document of informed consent indicating
their understanding of the investigational nature and risks of the study before any
protocol related studies are performed.


- Contraindication to trans-rectal biopsy:

- Bleeding disorder;

- PT/PTT greater than or equal to 1.5 times the upper limit of normal;

- Platelets less than or equal to 50K;

- Active anticoagulation;

- Severe immunocompromise;

- Severe hemorrhoids;

- Surgically absent rectum.

- Contraindication to MRI:

- Patients weighing greater than 136 kgs (weight limit for the scanner tables);

- Allergy to MR contrast agent;

- Patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable
electronic devices not compatible with MRI.

- Allergy to local anesthetics or quinolone antibiotics.

- Patients with a known diagnosis of prostate cancer and a known treatment plan to
proceed to prostatectomy if the result of the biopsy would not affect surgical

- Other medical conditions deemed by the PI or associates to make the patient
ineligible for protocol procedures.

Type of Study:


Study Design:


Principal Investigator

Kevin A Camphausen, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)


United States: Federal Government

Study ID:




Start Date:

April 2004

Completion Date:

Related Keywords:

  • Prostate Cancer
  • Prostate Cancer
  • MRI
  • Biopsy
  • Fiducial Marker
  • Prostatic Neoplasms



National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland  20892